Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT04856085




Registration number
NCT04856085
Ethics application status
Date submitted
21/04/2021
Date registered
22/04/2021
Date last updated
24/04/2024

Titles & IDs
Public title
Study of VIR-2218, VIR-3434, and/or PEG-IFNa in Subjects With Chronic Hepatitis B Virus Infection
Scientific title
A Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of Regimens Containing VIR-2218, VIR-3434, and/or PEG-IFNa in Subjects With Chronic Hepatitis B Virus Infection
Secondary ID [1] 0 0
VIR-2218-1006
Universal Trial Number (UTN)
Trial acronym
MARCH
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Hepatitis B, Chronic 0 0
Condition category
Condition code
Infection 0 0 0 0
Other infectious diseases
Oral and Gastrointestinal 0 0 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - VIR-2218
Treatment: Drugs - VIR-3434
Treatment: Drugs - PEG-IFNa

Experimental: Cohort 1a (VIR-2218 + VIR-3434) - Participants will receive multiple lead-in doses of VIR-2218, then combination therapy with VIR-2218 + VIR-3434 for 20 weeks total

Experimental: Cohort 2a (VIR-2218 + VIR-3434) - Participants will receive multiple lead-in doses of VIR-2218, then combination therapy with VIR-2218 + VIR-3434 for 20 weeks total

Experimental: Cohort 3a (VIR-2218 + VIR-3434) - Participants will receive multiple doses of VIR-2218 + VIR-3434 for 4 weeks

Experimental: Cohort 4a (VIR-2218 + VIR-3434) - Participants will receive multiple doses of VIR-2218 + VIR-3434 for 4 weeks

Experimental: Cohort 5a (VIR-2218 + VIR-3434) - Participants will receive multiple doses of VIR-2218 + VIR-3434 for 11 weeks

Experimental: Cohort 6a (VIR-2218 + VIR-3434) - Participants will receive multiple doses of VIR-2218 + VIR-3434 for 11 weeks

Experimental: Cohort 7a (VIR-2218 + VIR-3434) - Participants will receive multiple doses of VIR-2218 + VIR-3434 for 44 weeks

Experimental: Cohort 8a (VIR-2218 + VIR-3434) - Participants will receive multiple doses of VIR-2218 + VIR-3434 for 20 weeks

Experimental: Cohort 1b (VIR-3434) - Participants will receive multiple doses of VIR-3434 for 44 weeks

Experimental: Cohort 2b (VIR-3434) - Participants will receive multiple doses of VIR-3434 for 20 weeks

Experimental: Cohort 1c (VIR-2218 + VIR-3434 + PEG-IFNa) - Participants will receive multiple doses of VIR-2218 + VIR-3434 + PEG-IFNa for 24 weeks

Experimental: Cohort 2c (VIR-2218 + VIR-3434 + PEG-IFNa) - Participants will receive multiple doses of VIR-2218 + VIR-3434 + PEG-IFNa for 48 weeks

Experimental: Cohort 1d (VIR-3434 + PEG-IFNa) - Participants will receive multiple doses of VIR-3434 + PEG-IFNa for 48 weeks


Treatment: Drugs: VIR-2218
VIR-2218 given by subcutaneous injection

Treatment: Drugs: VIR-3434
VIR-3434 given by subcutaneous injection

Treatment: Drugs: PEG-IFNa
PEG-IFNa given by subcutaneous injection
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Proportion of participants with treatment-emergent adverse events (TEAEs)
Timepoint [1] 0 0
Up to 110 weeks
Primary outcome [2] 0 0
Proportion of participants with serious adverse events (SAEs)
Timepoint [2] 0 0
Up to 116 weeks
Primary outcome [3] 0 0
Proportion of participants with hepatitis B surface antigen (HBsAg) loss (defined as undetectable HBsAg) at end of treatment
Timepoint [3] 0 0
Up to 48 weeks
Primary outcome [4] 0 0
Proportion of participants with HBsAg loss (defined as undetectable HBsAg) at 24 weeks post-end of treatment
Timepoint [4] 0 0
Up to 72 weeks
Secondary outcome [1] 0 0
Absolute serum HBsAg and change from baseline across all timepoints in the study
Timepoint [1] 0 0
Up to 110 weeks
Secondary outcome [2] 0 0
Nadir and maximum reduction of serum HBsAg from baseline
Timepoint [2] 0 0
Up to 110 weeks
Secondary outcome [3] 0 0
Proportion of participants achieving sustained suppression of HBV DNA (< lower limit of quantification (LLOQ) for >= 24 weeks after discontinuation of all treatment, including NRTIs)
Timepoint [3] 0 0
Up to 110 weeks
Secondary outcome [4] 0 0
For hepatitis B e-antigen (HBeAg)-positive participants: Proportion of participants with HBeAg loss (undetectable HBeAg) and/or anti-HBe seroconversion at any timepoint
Timepoint [4] 0 0
Up to 110 weeks
Secondary outcome [5] 0 0
For HBeAg-positive participants: Time to HBeAg loss (undetectable HBeAg) and/or anti-HBe seroconversion
Timepoint [5] 0 0
Up to 110 weeks
Secondary outcome [6] 0 0
Cmax
Timepoint [6] 0 0
Up to 110 weeks
Secondary outcome [7] 0 0
Clast
Timepoint [7] 0 0
Up to 110 weeks
Secondary outcome [8] 0 0
Tmax
Timepoint [8] 0 0
Up to 110 weeks
Secondary outcome [9] 0 0
Tlast
Timepoint [9] 0 0
Up to 110 weeks
Secondary outcome [10] 0 0
AUCinf
Timepoint [10] 0 0
Up to 110 weeks
Secondary outcome [11] 0 0
AUClast
Timepoint [11] 0 0
Up to 110 weeks
Secondary outcome [12] 0 0
%AUCexp
Timepoint [12] 0 0
Up to 110 weeks
Secondary outcome [13] 0 0
t1/2
Timepoint [13] 0 0
Up to 110 weeks
Secondary outcome [14] 0 0
?z
Timepoint [14] 0 0
Up to 110 weeks
Secondary outcome [15] 0 0
Vz/F
Timepoint [15] 0 0
Up to 110 weeks
Secondary outcome [16] 0 0
CL/F
Timepoint [16] 0 0
Up to 110 weeks
Secondary outcome [17] 0 0
Number of participants with incidence and titers of anti-drug antibody (ADA) (if applicable) to VIR-3434
Timepoint [17] 0 0
Up to 110 weeks
Secondary outcome [18] 0 0
Proportion of participants meeting criteria for nucleotide reverse transcriptase inhibitors (NRTI) discontinuation
Timepoint [18] 0 0
Up to 60 weeks
Secondary outcome [19] 0 0
Proportion of participants meeting criteria for NRTI retreatment
Timepoint [19] 0 0
Up to 110 weeks
Secondary outcome [20] 0 0
Proportion of participants achieving undetectable HBsAg and sustained suppression of HBV DNA [below the LLOQ, target not detected (TND)] >/= 24 weeks after discontinuation of all treatment, including NRTIs
Timepoint [20] 0 0
Up to 110 weeks
Secondary outcome [21] 0 0
Proportion of participants with serum HBsAg < 10 IU/mL at end of treatment
Timepoint [21] 0 0
Up to 48 weeks
Secondary outcome [22] 0 0
Proportion of participants with serum HBsAg < 10 IU/mL at 24 weeks post-end of treatment
Timepoint [22] 0 0
Up to 72 weeks
Secondary outcome [23] 0 0
Proportion of participants with anti-HBs seroconversion
Timepoint [23] 0 0
Up to 110 weeks
Secondary outcome [24] 0 0
Time to achieve nadir of serum HBsAg
Timepoint [24] 0 0
Up to 110 weeks
Secondary outcome [25] 0 0
Time to achieve serum HBsAg loss
Timepoint [25] 0 0
Up to 110 weeks

Eligibility
Key inclusion criteria
- Male or female ages 18 - <66 years

- Chronic HBV infection for >/= 6 months

- On NRTI therapy for >/= 2 months at the time of screening
Minimum age
18 Years
Maximum age
65 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Any clinically significant chronic or acute medical condition that makes the
participant unsuitable for participation

- Significant fibrosis or cirrhosis

- History or evidence of drug or alcohol abuse

- History of chronic liver disease from any cause other than chronic HBV infection

- History of hepatic decompensation

- History of anaphylaxis

- History of allergic reactions, hypersensitivity, or intolerance to monoclonal
antibodies, antibody fragments, or any excipients of VIR-3434

- History of immune complex disease

- History of known contraindication to any interferon product

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
11/07/2021
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/06/2027
Actual
Sample size
Target
415
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Florida
Country [3] 0 0
United States of America
State/province [3] 0 0
Maryland
Country [4] 0 0
United States of America
State/province [4] 0 0
New Jersey
Country [5] 0 0
Canada
State/province [5] 0 0
Toronto
Country [6] 0 0
Canada
State/province [6] 0 0
Vancouver
Country [7] 0 0
Germany
State/province [7] 0 0
Frankfurt
Country [8] 0 0
Germany
State/province [8] 0 0
Hannover
Country [9] 0 0
Germany
State/province [9] 0 0
Mannheim
Country [10] 0 0
Germany
State/province [10] 0 0
Ulm
Country [11] 0 0
Hong Kong
State/province [11] 0 0
Shatin
Country [12] 0 0
Hong Kong
State/province [12] 0 0
Tai Po
Country [13] 0 0
Hong Kong
State/province [13] 0 0
Hong Kong
Country [14] 0 0
Korea, Republic of
State/province [14] 0 0
Busan
Country [15] 0 0
Korea, Republic of
State/province [15] 0 0
Seoul
Country [16] 0 0
Korea, Republic of
State/province [16] 0 0
Yangsan
Country [17] 0 0
Malaysia
State/province [17] 0 0
Batu Caves
Country [18] 0 0
Malaysia
State/province [18] 0 0
Kajang
Country [19] 0 0
Malaysia
State/province [19] 0 0
Kuala Lumpur
Country [20] 0 0
Moldova, Republic of
State/province [20] 0 0
Chisinau
Country [21] 0 0
New Zealand
State/province [21] 0 0
Auckland
Country [22] 0 0
New Zealand
State/province [22] 0 0
Hamilton
Country [23] 0 0
New Zealand
State/province [23] 0 0
Tauranga
Country [24] 0 0
New Zealand
State/province [24] 0 0
Wellington
Country [25] 0 0
Romania
State/province [25] 0 0
Bucharest
Country [26] 0 0
Taiwan
State/province [26] 0 0
Chiayi City
Country [27] 0 0
Taiwan
State/province [27] 0 0
Kaohsiung City
Country [28] 0 0
Taiwan
State/province [28] 0 0
Taichung City
Country [29] 0 0
Taiwan
State/province [29] 0 0
Taipei City
Country [30] 0 0
Taiwan
State/province [30] 0 0
Taoyuan City
Country [31] 0 0
Ukraine
State/province [31] 0 0
Kyiv
Country [32] 0 0
United Kingdom
State/province [32] 0 0
Birmingham
Country [33] 0 0
United Kingdom
State/province [33] 0 0
London
Country [34] 0 0
United Kingdom
State/province [34] 0 0
Manchester

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Vir Biotechnology, Inc.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This is a phase 2 study in which participants with chronic hepatitis B virus (HBV) infection
will receive VIR-2218, VIR-3434 and/or PEG-IFNa and be assessed for safety, tolerability, and
efficacy
Trial website
https://clinicaltrials.gov/ct2/show/NCT04856085
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Study Inquiry
Address 0 0
Country 0 0
Phone 0 0
415-654-5281
Fax 0 0
Email 0 0
clinicaltrials@vir.bio
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT04856085